Feed / VCYT

Veracyte, Inc.

VCYT

Healthcare · 40.85 -2.8% today

Isolated · not yet confirmedMarket checked 11 Sept, 15:55 GMT-4

Market read

Veracyte, Inc.'s current read is isolated; its market group is not confirming.

The latest filing evidence is available. 0 of 14 group members are active now; 0 filing-linked outsiders are moving with the group, and 0 of 10 directly disclosed connections are confirming.

What changed
  • Revenue increased 21.5% versus the comparable filing period.
Company-2.8% todayVolume comparison unavailable
Market group0 of 14 activeSafety & Protection · unavailable
Disclosed network0 of 8 confirmingNo filing-linked name is confirming now
What would change this read
  • Testing revenue grew 26% year-over-year, driven primarily by a 19% volume increase along with improved average selling price and collections.

Invalidation: The isolated read changes if VCYT's group or a disclosed connection begins moving with it.

Watch this read

Research brief

The story so far

Healthcare · Diagnostics & Research

The latest filing evidence is available. 0 of 14 group members are active now; 0 filing-linked outsiders are moving with the group, and 0 of 10 directly disclosed connections are confirming.

Evidence that supports
  • Revenue increased 21.5% versus the comparable filing period.
  • Operating margin improved 13.7 percentage points.
  • Net income increased 307.4% versus the comparable filing period.
Evidence that challenges

No thresholded adverse filing evidence is available yet.

What would clarify the read
  • Testing revenue grew 26% year-over-year, driven primarily by a 19% volume increase along with improved average selling price and collections.

Company research

Understand the business, not just the ticker

As of Sep 12, 2026
Business model and earnings drivers

Use the company’s filings to identify the few operating, demand, cost, capital and regulatory variables that determine its earnings power.

Key research questions
  • Which operating variable is changing?
  • Is that change durable, cyclical or one-off?
  • What evidence would disprove the current interpretation?
Annual periods9
Price observations328
Usable filing statements83
Verified relationships9
Evidence supporting the case
  • Latest annual revenue changed +16.0% year over year.
  • Operating margin changed +7.6 percentage points in the latest annual period.
  • Net margin changed +7.4 percentage points in the latest annual period.
Evidence challenging the case
  • Diluted shares increased 3.1% in the latest annual period.
  • Restructuring and cost reductions has repeated adverse evidence across 3 filings.
Questions before a position
  • P/E is 66% above the available filing-peer median; determine whether growth and quality justify the difference.
  • EV/sales is 158% above the available filing-peer median; determine whether growth and quality justify the difference.
Longer-term price context

Price as of Sep 11, 2026

40.85
6m+32.1%12m+32.5%24m—
Annual trajectory

Reported annual revenue and per-share history. This is accounting history, not a forecast.

PeriodRevenueYoYDiluted EPSShare change
2021-12-31$219.5M+86.8%$-1.11+27.5%
2022-12-31$296.5M+35.1%$-0.51+5.4%
2023-12-31$361.1M+21.8%$-1.02+1.5%
2024-12-31$445.8M+23.5%$0.31+7.6%
2025-12-31$517.1M+16.0%$0.82+3.1%

What management says matters

Persistent and emerging business drivers

Restructuring and cost reductionsnegative · 3 filings
“Biopharmaceutical and other revenue decreased by $3.5 million for the year ended December 31, 2025 compared to 2024, due to the decrease in the business conducted in France given the restructuring proceedings affecting Veracyte SAS in August 2025.”
10-K · Feb 26, 2026 ↗

Valuation discipline

Descriptive valuation snapshot

Price/sales 6.4× · EV/sales 5.7×. Comparisons use only industry-matched filing peers.

Scenario scaffold

Mechanical 2.0-year scenarios are available as editable assumptions, not consensus.

Price action

How the market is pricing the story

40.85-2.8% today

Jodie does not have enough daily observations to draw a useful short-term chart for this asset. The latest quoted price was checked 11 Sept, 15:55 GMT-4; this is a coverage limitation, not a flat-price conclusion.

Developments

No sourced recent-development timeline yet

Jodie has not returned a relevant primary source or news item for VCYT. This is an evidence-coverage gap, not a conclusion that nothing material happened.

Business and financial condition

Reported financial figures are not available yet

Jodie has not returned structured SEC XBRL fundamentals for this asset. This is a coverage limitation, not an assessment of the business or its financial health.

Latest filing assessment · baseline

Fundamentals strengthened in the latest filing

10-Q filed 2026-05-06 against the comparable filing from 2025-05-08.

constructive
OperationsconstructiveEvidence score +4
liquidityconstructiveEvidence score +1
valuationpremium

What improved

  • Revenue increased 21.5% versus the comparable filing period.
  • Operating margin improved 13.7 percentage points.
  • Net income increased 307.4% versus the comparable filing period.

What weakened

No thresholded deterioration was identified.

Filing receipts

“Cost of biopharmaceutical and other revenue for the three months ended March 31, 2026 decreased by $2.7 million compared to the same periods in 2025, driven primarily by a continued decline in biopharmaceutical services, as well as contract development and manufacturing services projects as a result of the restructuring proceedings affecting Veracyte SAS that were underway throughout 2025.”

“The Biopharmaceutical and other revenue decrease was due to the discontinuation of biopharmaceutical services, contract manufacturing or contract development services previously conducted in France, following the restructuring proceedings affecting Veracyte SAS, as of August 2025.”

“This was primarily due to a $27.8 million increase in testing revenue partially offset by a $3.3 million decrease in our biopharmaceutical and other revenue.”

Retrospective baseline calibration. It was generated after the filing date and is not part of Jodie's live track record.

Business ecosystem

The relationships behind VCYT

Customers, suppliers, partners and competitors named in company filings—not inferred from headlines.

Depends on

CAICaris Life Sciences, Inc.competitorFeb 26, 2026 ▾

“As we expand our portfolio of tests, including into the MRD space, we may also face competition from companies informing treatment decisions such as Natera, Inc., Guardant Health, Inc., Exact Sciences Corporation, Personalis, Myriad Genetics, Neogenomics, Inc…”

DGXQuest Diagnostics IncorporatedcompetitorFeb 26, 2026 ▾

“As we expand our portfolio of tests, including into the MRD space, we may also face competition from companies informing treatment decisions such as Natera, Inc., Guardant Health, Inc., Exact Sciences Corporation, Personalis, Myriad Genetics, Neogenomics, Inc…”

Depended on by

PSNLPersonalis, Inc.competitorMay 7, 2026 ▾

“Some of our present or potential competitors, including Adela, Inc., Caris Life Sciences, Inc., DELFI Diagnostics, Inc., Exact Sciences Corporation, which was acquired by Abbott Laboratories, Inc., in March 2026, Foresight Diagnostics Inc.”

Filing peers

LHCORXRN

Companies whose filings use similar operating language.

Open the three relationships above to see Jodie’s filing proof. Pro unlocks 8 more links, every receipt, and alerts when connected names begin moving. Unlock the full network →

What is moving around it

Live connections

VCYT is currently a Early Follower in the organic co-movement group Safety & Protection. This group is discovered from market behaviour rather than assigned from an industry taxonomy. 3 filing-linked names are in the relationship map; none is currently confirmed as moving with the group.

Context history

Theme membership history

No durable theme membership has been observed for this name yet.